Regeneron Showcases Cancer Care Advances at ESMO 2026
Regeneron presented late-breaking Phase 3 C-POST data on Libtayo in high-risk cutaneous squamous cell carcinoma and a Phase 2 analysis exploring Libtayo's potential in neoadjuvant treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.